Life Tech pairs with Novartis on cancer; Allergan rides device growth to strong Q2;

@FierceMedDev: Alere's losses triple as investor fight awaits. Story | Results | Follow @FierceMedDev

@MarkHFierce: Italy's Sorin has finally recovered from earthquake-related earnings challenges. Story | Follow @MarkHFierce

@DamianFierce: Siemens: Löscher's out; Kaeser's in; revenue's still sagging. Much more here: Report | Follow @DamianFierce

> Life Technologies ($LIFE) has signed a deal with Novartis ($NVS), allowing the drugmaker to use its modified T cell technology for cancer treatments. News

> GE Healthcare ($GE) submitted the final portion of its FDA application for a new breast imaging technology that uses tomosynthesis to provide 3-D images. More

> Allergan ($AGN) reported $1.6 billion in sales last quarter, a 10.6% increase sped along by a strong performance from its medical device business, which grew 7.4% to $229.3 million. Results

> Roche Diagnostics ($RHHBY) has launched a new automation system for its Cobas 8100 analyzers. Release

> Teleflex ($TFX) posted $420.1 million in revenue last quarter, a 9.6% jump, while net income stayed about flat at $42.4 million. Financials

> Episurf Medical won a CE mark for a new implant designed to treat cartilage damage in the knee. Item

Biotech News

@FierceBiotech: From Ex-Yahoo CEO backs genomics big data startup Bina. Article | Follow @FierceBiotech

@JohnCFierce: AstraZeneca commits $815M to partner with FibroGen on anemia drug. News | Follow @JohnCFierce

@RyanMFierce: There are no drugs approved specifically for Fragile X, a top genetic cause of autism and intellectual disability. More | Follow @RyanMFierce

@EmilyMFierce: New compound could combat castration-resistant prostate cancer. Story | Follow @EmilyMFierce

> NIH awards Third Rock startup up to $10M for Fragile X work. Item

> Buzz: Hungry AstraZeneca circles a blockbuster biosimilars buyout. Report

> Cubist splurges on Trius and Optimer buyouts to spur antibiotics growth. Article

> Report: Alexion allies with Goldman as Roche buyout rumor blazes. More

Pharma News

@FiercePharma: ICYMI yesterday: Pfizer unit pleads guilty, agrees to pay $491M in off-label marketing case. Report | Follow @FiercePharma

@CarlyHFierce: Rumors swirling about an AstraZeneca Celltrion buyout, but the Korean co. says nothing is definite. Celltrion's statement | Follow @CarlyHFierce

> FDA clears Merck's Januvia, sister meds of new pancreatitis worries. Story

> Sanofi swaps leaders at animal health unit Merial. Item

> Bayer's new drugs shine, fueling 5.5% pharma growth. Article

Drug Delivery News

@MichaelGFierce: Swedish team creates 'impossible' record-breaking drug delivery material. More | Follow @MichaelGFierce

> Mallinckrodt, Depomed win priority review for oral pain med. Report

> Aussie method makes for smaller, more efficient inhaled drugs. More

> DNA-based molecular robots zero in on cancer, autoimmune diseases. Article

> Mercator snags FDA patent for blood-pressure drug delivery catheters. Item

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.